Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323457 | 0.96 | MMP2 (0.38) | MMP2MMP9MMECAPN1LTA4H | |
| SCHEMBL20979822 | 0.94 | MMP2 (0.39) | MMP2MMP9MMECAPN1LTA4H | |
| SCHEMBL26542735 | 0.93 | CTSK (0.35) | MMP2MMP9MMECAPN1CTSL | |
| SCHEMBL20979796 | 0.90 | CTSB (0.38) | MMP2MMP9MMECTSLCTSB | |
| SCHEMBL20979759 | 0.89 | CAPN1 (0.35) | MMP2MMP9MMECAPN1CTSL | |
| SCHEMBL26362964 | 0.89 | MAPT (0.32) | MMP2MMP9CAPN1 | |
| SCHEMBL23295228 | 0.86 | CTSL (0.40) | CTSLCTSBCTSSCTSK | |
| SCHEMBL20979888 | 0.86 | CTSL (0.40) | CTSLCTSBCTSSCTSK | |
| SCHEMBL26543946 | 0.86 | CTSK (0.44) | CAPN1CTSLCTSBCTSSCTSK | |
| SCHEMBL22651693 | 0.85 | CTSL (0.31) | CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130315-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-06 | — | — | US | disclosed |
| EP-3480195-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | Bayer Animal Health GmbH (DE) | 2019-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130315-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | DNPEP, NPEPPS, PREP | MMP2 972/4885MMP9 1879/4885MME 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.